Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04973033
Other study ID # TofAV
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 1, 2019
Est. completion date January 31, 2021

Study information

Verified date July 2021
Source Shanghai Zhongshan Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this study is to evaluate the efficacy and safety of tofacitinib 5 mg twice daily in AAV patients.


Description:

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The predominantly used treatment for induction of remission in AAV consisted of cyclophosphamide (CYC) plus corticosteroids (GCs) which leads to remission in about 90% of patients. However, relapses are frequent and remain a challenge. The optimal drug for maintenance treatment is not determined. Tofacitinib is a Jak inhibitor which has been proved to be effective in multiple inflammatory diseases such as rheumatoid arthritis. Considering that T cells and associated cytokine production play an important role in the pathogenesis of AAV via activation of the JAK/ STAT pathway, we hypothesized that tofacitinib-mediated inhibition of JAK signaling may represent an effective therapy for active AAV. In this prospective, open label, single arm study, tofacitinib 5mg twice a day will be added to the background treatment of GCs and immunosuppressants in AAV, the safety and efficacy of tofacitinib will be assessed.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date January 31, 2021
Est. primary completion date January 31, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Patients with active AAV met the criteria of 1990 ACR and 2012 Chapel Hill criteria - Age 18 to 75 years - Written informed consent obtained before taking part in the study Exclusion Criteria: - Severe AAV defined as potentially organ- or life-threatening disease (i.e. alveolar haemorrhage, heart failure caused by myocarditis or pericarditis, progressive neurological symptoms, deaf, blindness, et al.) - Serum creatinine>120umol/L or proteinuria>1.0g/d - Receipt of a JAKi therapy previously - Co-existence of another systemic autoimmune disease - Secondary vasculitis (following neoplastic disease, an infection or antithyroid drugs) - Malignancy or history of malignancy - Infection by HIV, HCV, HBV or tuberculosis- - Severe uncontrolled cardiovascular, pulmonary, liver, gastrointestinal, endocrine, hematological, neurological, or psychiatric diseases that are not related to systemic vasculitis - Allergic to JAKi - Blood dyscrasias including confirmed: Hemoglobin <9 g/dL or Hematocrit <30%; White blood cell count <3.0 x 109/L; Absolute neutrophil count <1.5 x 109/L; Platelet count <100 x 109/L; Alanine transaminase or aspartate aminotransferase or total bilirubin>1.5 upper normal limit; Estimated glomerular filtration rate<60ml/min/1.73m2 - Incapacity or refusal to understand or sign the informed consent form. - Pregnancy, breastfeeding.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tofacitinib
patients enrolled were prescribed tofacitinib 5mg twice a day orally.

Locations

Country Name City State
China Department of Rheumatology in Zhongshan hospital, Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The response rate (CR, PR and TR) The percent of patients who achieved disease response. The disease response includes:(1) complete remission (CR), defined as the absence of disease activity (BVAS = 0); (2) partial remission (PR) defined as at least 50% reduction of BVAS and no new manifestations; (3) treatment resistance (TR) was defined as less than a 50% reduction or increased disease activity after 4 ~ 6 weeks of treatment. From the enrollment to the end of follow-up [0 to 13 months.]
Secondary The rate of adverse event The percent of different kinds of adverse events occurred during follow-up. The adverse event was evaluated according to the CTC-AE 4.0 standard. From the enrollment to the end of follow-up [0 to 13 months].
Secondary Changes in erythrocyte sedimentation rate (ESR) The change of ESR in different follow-up point compared with the baseline. From the enrollment to the end of follow-up [0 to 13 months].
Secondary Changes in CRP The change of CRP in different follow-up point compared with the baseline. From the enrollment to the end of follow-up [0 to 13 months].
Secondary Changes in glucocorticoids steroids (GCs) dosage The change of the prednisone or its equivalent drug in different follow-up point compared with the baseline. From the enrollment to the end of follow-up [0 to 13 months].
See also
  Status Clinical Trial Phase
Completed NCT05468879 - Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects N/A
Not yet recruiting NCT06395129 - Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
Completed NCT02293057 - Gender-Responsive Drug Use Treatment for Juvenile Justice Girls N/A
Completed NCT01941108 - Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care N/A
Completed NCT01380613 - Neighborhoods, Networks, Depression, and HIV Risk Phase 2
Withdrawn NCT00914719 - Alcohol Use and Sexual Risk: An Intervention N/A
Recruiting NCT03671629 - Pharmacist Intervention to Reduce Drug-related Readmissions Among the Elderly N/A
Completed NCT03290391 - Linking Infectious and Narcology Care-Part II Phase 4
Completed NCT04008927 - A Community-based Intervention Among Active Drug Users in Montpellier N/A
Completed NCT03627546 - HCV Seek, Test and Rapid Treatment for Young PWID N/A
Not yet recruiting NCT03967262 - Secondary Prevention and Recidivism Reduction in Trauma Patients N/A
Completed NCT03079856 - Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER N/A
Completed NCT03855410 - Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention N/A
Terminated NCT02457949 - The Impact of Alternative Social Assistance Disbursement on Drug-related Harm N/A
Completed NCT06238154 - Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds Phase 4
Terminated NCT04436055 - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Recruiting NCT04717856 - Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA N/A
Completed NCT00249496 - Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1 N/A
Recruiting NCT05597865 - Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents N/A
Completed NCT05553054 - Drug Wastage : Observational Study in Intensive Care Units in France